View in EDS

Tiragolumab in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (MORPHEUS-Liver): a randomised, open-label, phase 1b-2, study.

Saved in:
Bibliographic Details
Title: Tiragolumab in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (MORPHEUS-Liver): a randomised, open-label, phase 1b-2, study.
Authors: Finn RS; University of California Los Angeles (UCLA), Los Angeles, CA, USA. Electronic address: rfinn@mednet.ucla.edu., Ryoo BY; Asan Medical Center, Seoul, South Korea., Hsu CH; National Taiwan University Hospital, Taipei, Taiwan., Li D; City of Hope Comprehensive Cancer Center, Los Angeles, CA, USA., Burgoyne AM; UC San Diego, San Diego, CA, USA., Cotter C; Genentech, South San Francisco, CA, USA., Badhrinarayanan S; Genentech, South San Francisco, CA, USA., Wang Y; Genentech, South San Francisco, CA, USA., Yin A; Roche (China) Holding, Shanghai, China., Edubilli TR; Roche Products, Welwyn Garden City, UK., Mahrus S; Genentech, South San Francisco, CA, USA., Secrest MH; Genentech, South San Francisco, CA, USA., Shemesh CS; Genentech, South San Francisco, CA, USA., Yu N; Genentech, South San Francisco, CA, USA., Hack SP; Genentech, South San Francisco, CA, USA., Cha E; Genentech, South San Francisco, CA, USA., Gane E; University of Auckland, Auckland, New Zealand.
Source: The Lancet. Oncology [Lancet Oncol] 2025 Feb; Vol. 26 (2), pp. 214-226. Date of Electronic Publication: 2025 Jan 21.
Publication Type: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase I; Multicenter Study; Clinical Trial, Phase II
Journal Info: Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 39855251
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Tiragolumab in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (MORPHEUS-Liver): a randomised, open-label, phase 1b-2, study.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Finn+RS%22">Finn RS</searchLink>; University of California Los Angeles (UCLA), Los Angeles, CA, USA. Electronic address: rfinn@mednet.ucla.edu.<br /><searchLink fieldCode="AU" term="%22Ryoo+BY%22">Ryoo BY</searchLink>; Asan Medical Center, Seoul, South Korea.<br /><searchLink fieldCode="AU" term="%22Hsu+CH%22">Hsu CH</searchLink>; National Taiwan University Hospital, Taipei, Taiwan.<br /><searchLink fieldCode="AU" term="%22Li+D%22">Li D</searchLink>; City of Hope Comprehensive Cancer Center, Los Angeles, CA, USA.<br /><searchLink fieldCode="AU" term="%22Burgoyne+AM%22">Burgoyne AM</searchLink>; UC San Diego, San Diego, CA, USA.<br /><searchLink fieldCode="AU" term="%22Cotter+C%22">Cotter C</searchLink>; Genentech, South San Francisco, CA, USA.<br /><searchLink fieldCode="AU" term="%22Badhrinarayanan+S%22">Badhrinarayanan S</searchLink>; Genentech, South San Francisco, CA, USA.<br /><searchLink fieldCode="AU" term="%22Wang+Y%22">Wang Y</searchLink>; Genentech, South San Francisco, CA, USA.<br /><searchLink fieldCode="AU" term="%22Yin+A%22">Yin A</searchLink>; Roche (China) Holding, Shanghai, China.<br /><searchLink fieldCode="AU" term="%22Edubilli+TR%22">Edubilli TR</searchLink>; Roche Products, Welwyn Garden City, UK.<br /><searchLink fieldCode="AU" term="%22Mahrus+S%22">Mahrus S</searchLink>; Genentech, South San Francisco, CA, USA.<br /><searchLink fieldCode="AU" term="%22Secrest+MH%22">Secrest MH</searchLink>; Genentech, South San Francisco, CA, USA.<br /><searchLink fieldCode="AU" term="%22Shemesh+CS%22">Shemesh CS</searchLink>; Genentech, South San Francisco, CA, USA.<br /><searchLink fieldCode="AU" term="%22Yu+N%22">Yu N</searchLink>; Genentech, South San Francisco, CA, USA.<br /><searchLink fieldCode="AU" term="%22Hack+SP%22">Hack SP</searchLink>; Genentech, South San Francisco, CA, USA.<br /><searchLink fieldCode="AU" term="%22Cha+E%22">Cha E</searchLink>; Genentech, South San Francisco, CA, USA.<br /><searchLink fieldCode="AU" term="%22Gane+E%22">Gane E</searchLink>; University of Auckland, Auckland, New Zealand.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22100957246%22">The Lancet. Oncology</searchLink> [Lancet Oncol] 2025 Feb; Vol. 26 (2), pp. 214-226. <i>Date of Electronic Publication: </i>2025 Jan 21.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase I; Multicenter Study; Clinical Trial, Phase II
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Lancet+Pub%2E+Group%22">Lancet Pub. Group </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>100957246 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1474-5488 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2214702045%22">14702045 </searchLink><i>NLM ISO Abbreviation: </i>Lancet Oncol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=39855251
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/S1470-2045(24)00679-X
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 214
    Titles:
      – TitleFull: Tiragolumab in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (MORPHEUS-Liver): a randomised, open-label, phase 1b-2, study.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Finn RS
      – PersonEntity:
          Name:
            NameFull: Ryoo BY
      – PersonEntity:
          Name:
            NameFull: Hsu CH
      – PersonEntity:
          Name:
            NameFull: Li D
      – PersonEntity:
          Name:
            NameFull: Burgoyne AM
      – PersonEntity:
          Name:
            NameFull: Cotter C
      – PersonEntity:
          Name:
            NameFull: Badhrinarayanan S
      – PersonEntity:
          Name:
            NameFull: Wang Y
      – PersonEntity:
          Name:
            NameFull: Yin A
      – PersonEntity:
          Name:
            NameFull: Edubilli TR
      – PersonEntity:
          Name:
            NameFull: Mahrus S
      – PersonEntity:
          Name:
            NameFull: Secrest MH
      – PersonEntity:
          Name:
            NameFull: Shemesh CS
      – PersonEntity:
          Name:
            NameFull: Yu N
      – PersonEntity:
          Name:
            NameFull: Hack SP
      – PersonEntity:
          Name:
            NameFull: Cha E
      – PersonEntity:
          Name:
            NameFull: Gane E
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 02
              Text: 2025 Feb
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 1474-5488
          Numbering:
            – Type: volume
              Value: 26
            – Type: issue
              Value: 2
          Titles:
            – TitleFull: The Lancet. Oncology
              Type: main
ResultId 1